Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00341913 · ClinicalTrials.gov registry record
Network on Antimicrobial Resistance in Staphylococcus Aureus
A clinical trial of Staphylococcus Aureus, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 1
- Study location
NCT00341913: Completed study of Staphylococcus Aureus, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00341913 is a study of Staphylococcus Aureus that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00341913, a study of Staphylococcus Aureus, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 1
- Study location
Study Summary
Reduced susceptibility of Staphyloccus aureus to the glycopeptide antibiotic vancomycin is causing increasing concern worldwide in view of the threat of increased morbidity and mortality caused by such resistant organisms. MRL Pharmaceutical Services, a Division of Focus/MRL, has been contracted by NIAID to establish a Network on Antimicrobial Resistance in S. aureus (NARSA) to document cases where staphylococcal isolates with reduced susceptibility to vancomycin (MIC's greater than or equal to 4 micrograms/ml) have arisen and to procure such isolates into a central repository for distribution to registered approved researchers. MRL will be responsible for contacting sites where such isolates have been reported to discuss the test methods used to determine the reduced vancomycin susceptibility status of the isolate. Once the MRL Laboratory has determined that the isolate meets the criteria stated above, the site will be asked to ship the isolate to MRL as a possible candidate for inclusion in the NARSA Repository. The procurement strategy will involve issuing each isolate a temporary strain designation number which will be destroyed once the antibiotic profile of the isolate has been confirmed at MRL, thus preventing any link to the data generated by the site. The isolate and its antimicrobial susceptibility profile to several key drugs will be recorded in the NARSA Repository database. Demographic information related to the isolate and collected from the site includes: The Name of the Donor Site/Institution, City (to be held in a separate secured database, these data points are not available to registered user); State, Country of Donor Site; Isolation Date; Age; Sex; Patient Location; Patient Service; Culture Source; Reporting History. This information will be held in the Registry database. Since patient-specific information will not be collected, a request for a waiver of informed consent has been requested herein. NIAID funded investigators (NARSA Core Investig
Conditions Studied
Study Locations (1)
Virginia
- MRL Pharmaceutical Services - Herndon
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-03-16 |
| Est. Completion | 2008-06-17 |
What the finished NCT00341913 record still lists
NCT00341913 is an observational study that tracks outcomes without assigning an intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Staphylococcus Aureus appearing as the primary indexed condition, and to 0 interventions.
NCT00341913 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT00341913 about?
NCT00341913 is a clinical study titled "Network on Antimicrobial Resistance in Staphylococcus Aureus". Reduced susceptibility of Staphyloccus aureus to the glycopeptide antibiotic vancomycin is causing increasing concern worldwide in view of the threat of increased morbidity and mortality caused by such resistant organisms. MRL Pharmaceutical Services, a Division of Focus/MRL, has been contracted by ...
What is the current status of trial NCT00341913?
This trial is currently completed. The study started on 2000-03-16. Estimated completion is 2008-06-17.
What conditions does trial NCT00341913 study?
This clinical trial studies the following conditions: Staphylococcus Aureus.
Who is sponsoring clinical trial NCT00341913?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00341913 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Staphylococcus Aureus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome
RECRUITING · Phase 1
-
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
RECRUITING · Phase 1
-
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
RECRUITING · Phase 4
-
Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Risk Factors for Linezolid Resistance in Staphylococcus Aureus
COMPLETED
-
A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI